TriSalus Life Sciences, Inc. (TLSI) Discusses Pressure-Enabled Drug Delivery and Advances in Uterine Fibroid Embolization Transcript [Seeking Alpha]
TriSalus Life Sciences, Inc. (TLSI)
Company Research
Source: Seeking Alpha
Company Participants Mary Szela - CEO, President & Director Richard Marshall Andrea Marasso Conference Call Participants Nicole Lamparello Francis Kang Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Justin Walsh - JonesTrading Institutional Services, LLC, Research Division Presentation Operator Good morning, and welcome to the TriSalus Life Sciences KOL event. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made available on the TriSalus website following the conclusion of the event. I'd now like to turn the call over to Mary Szela, Chief Executive Officer and President of TriSalus Life Sciences. Please go ahead, Mary. Mary Szela CEO, President & Director Welcome, everyone, and thank you so much for joining. This is the first or our inaugural webinar in a series of webinars that help illustrate the value of our technology. And I'm very excited to report that we have two distinguished physicia
Show less
Read more
Impact Snapshot
Event Time:
TLSI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TLSI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TLSI alerts
High impacting TriSalus Life Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
TLSI
News
- TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TLSI&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
- TriSalus Life Sciences (NASDAQ:TLSI) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TLSI&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall MarketBeat
- TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue GuidanceBusiness Wire
- TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.MarketBeat
- TriSalus Life Sciences (NASDAQ:TLSI) had its price target raised by analysts at Canaccord Genuity Group Inc. from $11.00 to $12.00. They now have a "buy" rating on the stock.MarketBeat
TLSI
Earnings
- 11/13/25 - Miss
TLSI
Analyst Actions
- 12/17/25 - Canaccord Genuity
TLSI
Sec Filings
- 1/12/26 - Form 8-K
- 12/5/25 - Form EFFECT
- 11/25/25 - Form 4
- TLSI's page on the SEC website